Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs

Kohji Takara, Yusuke Tanigawara, Fusao Komada, Kohshi Nishiguchi, Toshiyuki Sakaeda, Katsuhiko Okumura

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The reversal effect of itraconazole on P-glycoprotein (P-gp)-mediated resistance of vinblastine, daunorubicin and doxorubicin was analyzed from a cellular pharmacokinetic point of view, namely by [3H]azidopine photoaffinity labeling, intracellular accumulation and transcellular transport experiments. The LLC-GA5COL150 cells, which expressed human P-gp selectively on the apical membrane due to transfection of MDR1 cDNA into the porcine kidney epithelial cells (LLC-PK1 cells), was used here, since this cell line constructs the monolayer with tight junction, being able to characterize the cellular pharmacokinetics. In LLC-GA5-COL150 cells, itraconazole caused a reversal from resistance as shown by a growth inhibition assay. [3H]Azidopine photoaffinity labeling demonstrated that itraconazole, vinblastine, daunorubicin and doxorubicin showed higher binding ability for P-gp compared with digoxin, suggesting the following results were via P-gp. The intracellular accumulation of [3H]vinblastine, [3H]daunorubicin and [14C]doxorubicin after their application on the basal and apical sides was increased by itraconazole. These changes were similar to the dose modifying factors determined by the growth inhibition assay. However, their basal-to-apical transport was hardly affected by itraconazole, and this was explained by the fact that itraconazole inhibited P-gp, and subsequently increased their intracellular concentration and then the non-P- gp mediated transport from the intracellular space to apical side. The apicalto-basal transport of [3H]vinblastine, [3H]daunorubicin and [14C]doxorubicin was increased by itraconazole, and this was reasonably explained by the inhibition of P-gp, and partly also by the increase of their intracellular concentration via the inhibition of P-gp.

Original languageEnglish
Pages (from-to)1355-1359
Number of pages5
JournalBiological and Pharmaceutical Bulletin
Volume22
Issue number12
Publication statusPublished - 1999 Dec

Fingerprint

Itraconazole
P-Glycoprotein
Drug Resistance
Pharmacokinetics
Daunorubicin
Vinblastine
Doxorubicin
Intracellular Space
LLC-PK1 Cells
Transcytosis
Tight Junctions
Digoxin
Transfection
Intercellular Signaling Peptides and Proteins
Swine
Complementary DNA
Epithelial Cells
Kidney
Cell Line
Membranes

Keywords

  • Cellular pharmacokinetic analysis
  • Multidrug resistance
  • P-glycoprotein
  • Reversal effect of itraconazole

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs. / Takara, Kohji; Tanigawara, Yusuke; Komada, Fusao; Nishiguchi, Kohshi; Sakaeda, Toshiyuki; Okumura, Katsuhiko.

In: Biological and Pharmaceutical Bulletin, Vol. 22, No. 12, 12.1999, p. 1355-1359.

Research output: Contribution to journalArticle

Takara, Kohji ; Tanigawara, Yusuke ; Komada, Fusao ; Nishiguchi, Kohshi ; Sakaeda, Toshiyuki ; Okumura, Katsuhiko. / Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs. In: Biological and Pharmaceutical Bulletin. 1999 ; Vol. 22, No. 12. pp. 1355-1359.
@article{4ef9453a50b64920a3cd3b7868edfa07,
title = "Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs",
abstract = "The reversal effect of itraconazole on P-glycoprotein (P-gp)-mediated resistance of vinblastine, daunorubicin and doxorubicin was analyzed from a cellular pharmacokinetic point of view, namely by [3H]azidopine photoaffinity labeling, intracellular accumulation and transcellular transport experiments. The LLC-GA5COL150 cells, which expressed human P-gp selectively on the apical membrane due to transfection of MDR1 cDNA into the porcine kidney epithelial cells (LLC-PK1 cells), was used here, since this cell line constructs the monolayer with tight junction, being able to characterize the cellular pharmacokinetics. In LLC-GA5-COL150 cells, itraconazole caused a reversal from resistance as shown by a growth inhibition assay. [3H]Azidopine photoaffinity labeling demonstrated that itraconazole, vinblastine, daunorubicin and doxorubicin showed higher binding ability for P-gp compared with digoxin, suggesting the following results were via P-gp. The intracellular accumulation of [3H]vinblastine, [3H]daunorubicin and [14C]doxorubicin after their application on the basal and apical sides was increased by itraconazole. These changes were similar to the dose modifying factors determined by the growth inhibition assay. However, their basal-to-apical transport was hardly affected by itraconazole, and this was explained by the fact that itraconazole inhibited P-gp, and subsequently increased their intracellular concentration and then the non-P- gp mediated transport from the intracellular space to apical side. The apicalto-basal transport of [3H]vinblastine, [3H]daunorubicin and [14C]doxorubicin was increased by itraconazole, and this was reasonably explained by the inhibition of P-gp, and partly also by the increase of their intracellular concentration via the inhibition of P-gp.",
keywords = "Cellular pharmacokinetic analysis, Multidrug resistance, P-glycoprotein, Reversal effect of itraconazole",
author = "Kohji Takara and Yusuke Tanigawara and Fusao Komada and Kohshi Nishiguchi and Toshiyuki Sakaeda and Katsuhiko Okumura",
year = "1999",
month = "12",
language = "English",
volume = "22",
pages = "1355--1359",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "12",

}

TY - JOUR

T1 - Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs

AU - Takara, Kohji

AU - Tanigawara, Yusuke

AU - Komada, Fusao

AU - Nishiguchi, Kohshi

AU - Sakaeda, Toshiyuki

AU - Okumura, Katsuhiko

PY - 1999/12

Y1 - 1999/12

N2 - The reversal effect of itraconazole on P-glycoprotein (P-gp)-mediated resistance of vinblastine, daunorubicin and doxorubicin was analyzed from a cellular pharmacokinetic point of view, namely by [3H]azidopine photoaffinity labeling, intracellular accumulation and transcellular transport experiments. The LLC-GA5COL150 cells, which expressed human P-gp selectively on the apical membrane due to transfection of MDR1 cDNA into the porcine kidney epithelial cells (LLC-PK1 cells), was used here, since this cell line constructs the monolayer with tight junction, being able to characterize the cellular pharmacokinetics. In LLC-GA5-COL150 cells, itraconazole caused a reversal from resistance as shown by a growth inhibition assay. [3H]Azidopine photoaffinity labeling demonstrated that itraconazole, vinblastine, daunorubicin and doxorubicin showed higher binding ability for P-gp compared with digoxin, suggesting the following results were via P-gp. The intracellular accumulation of [3H]vinblastine, [3H]daunorubicin and [14C]doxorubicin after their application on the basal and apical sides was increased by itraconazole. These changes were similar to the dose modifying factors determined by the growth inhibition assay. However, their basal-to-apical transport was hardly affected by itraconazole, and this was explained by the fact that itraconazole inhibited P-gp, and subsequently increased their intracellular concentration and then the non-P- gp mediated transport from the intracellular space to apical side. The apicalto-basal transport of [3H]vinblastine, [3H]daunorubicin and [14C]doxorubicin was increased by itraconazole, and this was reasonably explained by the inhibition of P-gp, and partly also by the increase of their intracellular concentration via the inhibition of P-gp.

AB - The reversal effect of itraconazole on P-glycoprotein (P-gp)-mediated resistance of vinblastine, daunorubicin and doxorubicin was analyzed from a cellular pharmacokinetic point of view, namely by [3H]azidopine photoaffinity labeling, intracellular accumulation and transcellular transport experiments. The LLC-GA5COL150 cells, which expressed human P-gp selectively on the apical membrane due to transfection of MDR1 cDNA into the porcine kidney epithelial cells (LLC-PK1 cells), was used here, since this cell line constructs the monolayer with tight junction, being able to characterize the cellular pharmacokinetics. In LLC-GA5-COL150 cells, itraconazole caused a reversal from resistance as shown by a growth inhibition assay. [3H]Azidopine photoaffinity labeling demonstrated that itraconazole, vinblastine, daunorubicin and doxorubicin showed higher binding ability for P-gp compared with digoxin, suggesting the following results were via P-gp. The intracellular accumulation of [3H]vinblastine, [3H]daunorubicin and [14C]doxorubicin after their application on the basal and apical sides was increased by itraconazole. These changes were similar to the dose modifying factors determined by the growth inhibition assay. However, their basal-to-apical transport was hardly affected by itraconazole, and this was explained by the fact that itraconazole inhibited P-gp, and subsequently increased their intracellular concentration and then the non-P- gp mediated transport from the intracellular space to apical side. The apicalto-basal transport of [3H]vinblastine, [3H]daunorubicin and [14C]doxorubicin was increased by itraconazole, and this was reasonably explained by the inhibition of P-gp, and partly also by the increase of their intracellular concentration via the inhibition of P-gp.

KW - Cellular pharmacokinetic analysis

KW - Multidrug resistance

KW - P-glycoprotein

KW - Reversal effect of itraconazole

UR - http://www.scopus.com/inward/record.url?scp=0033372992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033372992&partnerID=8YFLogxK

M3 - Article

C2 - 10746169

AN - SCOPUS:0033372992

VL - 22

SP - 1355

EP - 1359

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 12

ER -